Expert Interview
What Can We Expect from the Phase 2b Data of Supernus' ADHD drug SPN-812?
Ticker(s): SUPNA psychiatrist with significant experience treating ADHD and a familiarity with SPN-812 (viloxazine hydrochloride).
What is your experience treating children with ADHD? About how many do you see each year, and of those, how many would SPN-812 be a potential treatment?
Added By: kcmckeeWhat are your current treatments of choice for ADHD? What are their pros and cons, and what are you looking for in a treatment to replace them?
Added By: kcmckeeWhat are your thoughts on the data behind SPN-812? How does its widespread european use as an antidepressant have bearing on its potential as an ADHD medication?
Added By: kcmckeeWhat has kept viloxazine hydrochloride out of the U.S. market in your opinion? Do you think the data behind SPN-812 suggests any potential to come stateside?
Added By: kcmckeeDo you see many mental health treatments being used to treat a broad range of issues? Are there other drugs on the market used to treat ADHD in addition to something else? What would you expect the Phase 2b data to suggest about the drug.
Added By: kcmckeeWith a variety of ADHD treatments currently available, does anything about the science or mechanism of action behind SPN-812 make you think it will be able to differentiate itself from the competition?
Added By: kcmckeeAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- Supernus (SUPN) Announces Early Release of Top-Line Phase 2b Data Evaluating ADHD drug SPN-812 SUPN Occurred On: Oct 11, 2016
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
